Mr. Reynolds leads our teams to commercialize our novel neurological science and technologies that were developed at Massachusetts Institute of Technology and Harvard Medical School.

Prior to joining InVivo Therapeutics, Mr. Reynolds was Director, Global Business Development for Siemens Corporation were he was responsible for new business revenue in 132 countries. At Siemens, Frank won numerous awards including the 2005 Global Presidential Sales Award, and he was a 2004 Top+ USA Strategy Award winner for his initiatives in global sales force strategy and collaboration. Mr. Reynolds was Founder and CEO of Expand The Knowledge, Inc from 1997-2002. In addition, Mr. Reynolds has 10 years management experience primarily in healthcare related fields.

Mr. Reynolds won the prestigious “Top 40 Irish-American Executive Award” from the Irish-Echo the largest Ireland focused publication in the world.  Mr. Reynolds has been an Executive Board Member of the Ireland Chamber of Commerce of the United States since 1998. He is a graduate of the Sloan Fellows Program at the Massachusetts Institute of Technology where he completed his MBA and coursework at the Harvard Business School. His graduate school education includes a M.S. in Technology Management Program from The Wharton School of Business and a M.S. in Engineering from the University of Pennsylvania, a Masters in Health Administration from Saint Joseph University, a M.S. in Management Information Systems from Temple University, a M.S. in Psychology from Chestnut Hill College, and he received his Bachelors of Science in Marketing from Rider University.

Christopher Pritchard is responsible for product development and manufacturing of InVivo’s multi-disciplinary platform technologies.  In developing truly innovative technologies InVivo does not have comparative technologies that can provide a roadmap for product development or manufacturing.  InVivo relies on Christopher to harness the resources of MIT, Harvard, and industry to bring our treatment for spinal cord injuries and spinal cord tumors to market. 

As part of MIT’s Langer Lab Christopher is a candidate for a Ph.D. from MIT in the Department of Chemical Engineering and an MBA from the MIT-Sloan School of Management.  Christopher is the key collaborator with Neuroscientists from Harvard’s Brigham and Women’s Department of Neurosurgery including Teng Lab.

Christopher received his Masters in Engineering Science from the University of Oxford with First Class Honours.  At Oxford, he ranked second in his class, was awarded the Edgell Sheppee Prize for Excellent Performance.  Before joining InVivo, Christopher also spent a year at Princeton University, where he won an award for his research.  He holds an Engineering Leadership Award from the Royal Academy of Engineering.

Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written over 860 articles. He also has over 500 issued or pending patents worldwide, one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States. Dr. Langer’s patents have been licensed or sublicensed to over 100 pharmaceutical, chemical, biotechnology and medical device companies; a number of these companies were launched on the basis of these patent licenses. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995-2002 and as its Chairman from 1999-2002.

Dr. Langer has received over 140 major awards. In 2002, he received the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the world’s most prestigious engineering prize, from the National Academy of Engineering. He is the also the only engineer to receive the Gairdner Foundation International Award; 65 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005) and the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research. In 2006, he was inducted into the National Inventors Hall of Fame. In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine". In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.

Forbes Magazine (1999) and Bio World (1990) have named Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Langer as one of the 15 innovators world wide who will reinvent our future. Time Magazine and CNN (2001) named Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America. Parade Magazine (2004) selected Langer as one of 6 “Heroes whose research may save your life.” He has served, at various times, on 15 boards of directors and 30 Scientific Advisory Boards of such companies as Wyeth, Alkermes, Mitsubishi Pharmaceuticals, Warner-Lambert, and Momenta Pharmaceuticals Dr. Langer has received honorary doctorates from the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, the Pennsylvania State University, Northwestern University and Uppsala University (Sweden). He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

Dr. Roberts won the 1993 Nobel prize in Medicine and Physiology

Dr. Richard J. Roberts is the Chief Scientific Officer at New England Biolabs, Beverly, Massachusetts. He was educated in England, attending St. Stephen's School and the City of Bath Boys' School in Bath before moving to the University of Sheffield where he obtained a B.Sc. in Chemistry in 1965 and a Ph.D. in Organic Chemistry in 1968. His postdoctoral research was carried out in Professor J.L. Strominger's laboratory at Harvard, where he studied the tRNAs that are involved in the biosynthesis of bacterial cell walls. From 1972 to 1992, he worked at Cold Spring Harbor Laboratory, reaching the position of Assistant Director for Research under Dr. J.D. Watson.

He began work on the newly discovered Type II restriction enzymes in 1972 and in the next few years more than 100 such enzymes were discovered and characterized in Dr. Roberts' laboratory. His laboratory has cloned the genes for several restriction enzymes and their cognate methylases and studies of these enzymes has been a major research theme. Dr. Roberts has also been involved in studies of Adenovirus-2 beginning with studies of transcription that led to the discovery of split genes and mRNA splicing in 1977. This was followed by efforts to deduce the DNA sequence of the Adenovirus-2 genome and a complete sequence of 35,937 nucleotides was obtained. This latter project required the extensive use of computer methods, both for the assembly of the sequence and its subsequent analysis. His laboratory pioneered the application of computers in this area and the further development of computer methods of protein and nucleic acid sequence analysis continues to be a major research focus. The field of DNA methyltransferases is also an area of active research interest and crystal structures for the HhaI methyltransferase both alone and in complex with DNA have been obtained in collaboration with Dr. X. Cheng. The latter complex is quite remarkable as the protein causes the target cytosine base to flip completely out of the helix so that it is accessible for chemical reaction. This extreme, but elegant, distortion of the double helix had not been seen previously. A consuming interest at present is the semi-automatic identification of restriction enzyme and methylase genes within the GenBank database and the development of rapid methods to assay function. Already several new specificities have been found and it is clear that there are many more restriction enzyme genes in Nature than had been previously suspected.

Dr. Woodard, MD is Chief, Neurosurgery at New England Baptist Hospital in Boston.

Dr. Eric Woodard received his medical degree from the Pennsylvania State University and completed his residency in Neurological surgery at Emory University. Following residency Dr. Woodard completed a fellowship in complex spinal surgery at the Medical College of Wisconsin under Dr. Sanford Larsen.  He is a diplomat of the American Board of Neurological Surgeons.

Dr. Woodard was formerly Chief of the Division of Spinal Surgery in the Department of Neurological Surgery at Brigham and Women’s Hospital, where he held the rank of Assistant Professor in Surgery at Harvard Medical School.

Since joining the medicals staff in 2004 Dr. Woodard has continued to practice complex spinal surgery and has established the Neurosurgery Fellowship in spinal surgery at New England Baptist Hospital.  He has been an editorial board member for The Journal of Spinal Disorders, Spine Universe.com and is an ad hoc reviewer for Neurosurgery, Journal of Neurosurgery and the New England Journal of Medicine.

Dr. Woodard is a member numerous professional societies and organizations that include the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the Joint Section of the AANS/CNS, Spine and Peripheral Nerve, AO Spine North America, the North American Spine Society, Massachusetts Medical Society, and the Racchidian Society.  He is the immediate past- chairman of the AO Spine North America Board and serves on the Board of AO Spine International.

Dr. Woodard has published many articles and book chapters in the field of spine surgery and lectures extensively both nationally and internationally.  He lives in Boston with his wife and children.

Todd J. Albert, MD, is the James Edwards Professor and Chair of the Department of Orthopaedics at Jefferson Medical College in Philadelphia.  He is also the President of the Rothman Institute in Philadelphia.  

Previously, he served as Co-director of Reconstructive Spine Surgery and the Spine Fellowship Program at Thomas Jefferson University. Dr. Albert graduated magna cum laude from Amherst College, received his doctor of medicine degree from the University of Virginia School of Medicine, and completed a residency in Orthopaedic surgery at Thomas Jefferson University Hospital (where he was named Outstanding Chief Resident) and a fellowship in spinal surgery at the Minnesota Spine Center.

Dr. Albert serves on the boards of several scholarly journals, including Spine, The Spine Journal, and The Journal of Spinal Disorders and Techniques, as well as medical associations, including American Academy of Orthopaedic Surgery, Cervical Spine Research Society, Scoliosis Research Society, International Society for Study of the Lumbar Spine, and North American Spine Society. He is Chair of Network Development for the National Spine Network, a consortium of centers of excellence for spine care throughout the United States.

Dr. Albert has published over 200 scientific articles, authored over 40 book chapters, and presented his research both nationally and internationally. He has published seven textbooks on spinal surgery, including Spine Surgery: Tricks of the Trade; Surgical Approaches to the Spine; Master cases: Spine Surgery; Physical Examination of the Spine; and Spinal Deformities, The Essentials.

Dr. Slotkin is a clinical neurosurgeon and research scientist.

Clinically, Dr. Slotkin has expertise in complex spinal surgery, minimally-invasive spinal surgery, spinal oncology surgery, and brain tumor surgery.  Dr. Slotkin completed residency training in neurosurgery at Harvard Medical School, Brigham and Women’s Hospital.   He is the co-editor of a two volume publication on spinal surgery.  He is currently a clinical fellow in complex spinal surgery with Dr. Eric Woodard.

Dr. Slotkin’s research interests include regeneration and plasticity after spinal cord injury, and nanotechnology initiatives for cellular labeling and non-invasive cell tracking.  Dr. Slotkin has authored or co-authored several peer-reviewed scientific publications in the areas of repair after spinal cord injury in animal models, and in vivo quantum dot labeling of neural stem cells.   Dr. Slotkin has expertise in the application of nanotechnology research to clinical neurosurgery and neurology.  His work was awarded the Apfelbaum Award for Research by the American Association of Neurological Surgeons.  He is currently investigating stem cell and polymer scaffold repair of spinal cord injury and stroke in the laboratory of Dr. Ted Teng at Harvard Medical School.

Dr. Alexander R. Vaccaro is Co-Director of the Delaware Valley Regional Spinal Cord Injury Center at Thomas Jefferson University, one of the largest referral programs for spinal injury in the country.

He also serves as Co-Director of Reconstructive Spine Services at the Rothman Institute and as Co-Director of the Spine Fellowship at Thomas Jefferson University. Dr. Vaccaro graduated summa cum laude from Boston College. He received his medical degree from Georgetown University School of Medicine, where he graduated cum laude. He performed his surgical internship at Cedars-Sinai Medical Center in Los Angeles. He then completed a residency in Orthopaedic surgery at Thomas Jefferson University Hospital and a spine fellowship at the University of California at San Diego.

Dr. Vaccaro has received numerous awards commending his outstanding and prolific research, and has published and presented extensively on his findings. He has served as moderator or chairman at over 80 national and international spine symposiums. His recent textbook, Principles and Practices of Spine Surgery (2002), is used as a standard for spine care nationally and internationally. He serves as a Professor in the Department of Orthopaedic Surgery at Jefferson Medical College of Thomas Jefferson University and is a member of numerous medical societies.

In 2002 he was selected to be an American Orthopaedic Association Japanese Traveling Fellow where he lectured at numerous academic universities in Japan. In the summer of 2003 he toured Europe as a Scoliosis Research Society traveling fellow participating in surgery and lecturing on spinal deformity. In 2004 he was selected to be the executive editor of Orthopaedic Knowledge Update (OKU) 8, the latest edition of the premier Orthopaedic review textbook.

Mr. Lapidus is an experienced life-science entrepreneur. Helicos is his third life-science start-up. In 1995 he founded EXACT Sciences Corporation (NASDAQ: EXAS), an applied genomics company that develops and markets non-invasive, DNA-based methods for early detection of colorectal and other common cancers. He served as President from 1995 through 2000 and Chairman of EXACT Sciences' Board of Directors from 2000 through 2005. He continues to serve as a board member. Prior to EXACT, Mr. Lapidus founded Cytyc Corporation (NASDAQ:CYTC) and was President and CEO from 1987 through 1994. In addition to his entrepreneurial activities, Mr. Lapidus holds academic appointments in the Pathology Department at Tufts University Medical School and MIT's Sloan School of Management. He earned a BSEE from Cooper Union. He has served as a trustee of Cooper Union since 2002. Mr. Lapidus holds 29 issued patents.

Paul Mraz has been active in the Medical Device and Life Sciences Industry for over 17 years - in companies large and small, both venture backed and privately funded - with roles in executive management, product development, marketing, sales management and business development - all on a global basis.

Mr. Mraz currently serves as Chief Executive Officer of CeraPedics, Inc., a medical device company located outside Denver, CO.  CeraPedics is working toward commercializing products for the orthopaedic bone graft substitutes market based on its proprietary small peptide technology and recently completed a $14.5M Series A financing with OrbiMed Advisors, LLC.

Mr. Mraz most recently served as Chairman and CEO of Angstrom Medica, Inc. (acquired by Pioneer Surgical Technology), a privately funded, early-stage biomaterials nanotechnology company engaged in the development of structural, calcium phosphate-based medical devices for the spinal, sports medicine, and trauma markets. 

Prior to Angstrom Medica, Mr. Mraz was a Principal of Link Spine Group Inc., a start-up medical device company that developed and commercialized the world’s first total disc replacement for the lumbar spine.  Mr. Mraz served as Vice President - Worldwide Marketing and International Sales until its acquisition by Johnson & Johnson in June 2003.

Mr. Mraz was also a key management team member of three other early-stage medical device companies and his early experience includes positions at Figgie Medical Systems, Ortho Development Corporation (acquired by Japan MDM) and Marlow Surgical Technologies, Inc. (acquired by Cooper Surgical) as well as DePuy, Inc. and DePuy Spine (formerly AcroMed Corporation) – both acquired by  Johnson & Johnson in 1998.

Mr. Mraz also currently serves as a Director of superDimension, Ltd. (Herzliya, ISRAEL and Plymouth, MN), an emerging world leader in the minimally-invasive diagnosis and treatment of lung disease (e.g. cancer, emphysema) via interactive real-time guidance of endoscopic tools and bronchoscopy.

Mr. Mraz received a B.S. degree in Mechanical Engineering from Lafayette College and a M.S. degree in Mechanical Engineering and Biomechanics from Case Western Reserve University.  Mr. Mraz holds six US Patents for various medical devices and is an active advisor to numerous venture capital groups.  Mr. Mraz also enjoys mentoring and advising other entrepreneurs in the medical device industry worldwide.

David W. Feigal Jr., MD, joined Elan as Senior Vice President, Head of Global Regulatory and Global Safety Surveillance in November 2006. Prior to joining Elan, David spent 12 years with the FDA. During his time at the FDA he was Head of the Center for Devices for Five years and he was also Head of the Center for Biologics for five years.

Before joining the FDA, Dr. Feigal worked for 10 years within the academic and hospital settings of the University of California in San Diego, San Francisco and Davis. Dr. Feigal holds a BA from University of Minnesota, an MD from Stanford University and a Master of Public Health from the University of California, Berkeley.

Dr. Ellis was born in the United Kingdom, where he received a British Petroleum scholarship to the University of St. Andrews. He earned an Honors degree in Chemistry in 1964, followed by a Ph.D. in Biophysics in 1967. After university, he joined 3i Group PLC, the largest private equity manager in the world. After attending the Sloan School of MIT, Dr. Ellis was selected to found and lead the team responsible for 3i’s technology investments and turnaround investments, where he had oversight of over 100 private equity investments.

From 1975 to 1981, David held operational roles in the U.K. and the U.S.:

• COO and CEO of B.H. Blackwell Ltd., the world’s largest distributor of library materials. Acquired its largest competitor, Richard Abel & Company (Portland, Oregon).

• CFO of Software Sciences International Ltd., a computer systems group specializing in defense systems, air traffic control and newspaper automation.  Orchestrated the sale to BOC Group plc.

• CEO of Software Sciences Inc. In the U.S. book industry, Dr. Ellis introduced specialized point-of-sale systems, back-office inventory control systems, and MIS systems, most notably in association with the Ingram Book Company.

In 1988, David and Sal Massaro launched the EGL investment business. Based on David’s relationships in British finance circles, he raised capital for U.S. venture investments, initially from Mercury Asset Management (MAM), followed later by National Westminster Bank (Natwest). EGL invested in a range of sectors, including information technology, healthcare, instrumentation, manufacturing, and distribution businesses at all stages of development. All investments have been realized. David has also been active as an Angel investor with current investments in Metabolic Testing Services (MTShealth.com), The Gideon Group (thegideongroup.com) and SugarLoaf Products (sugarloafproducts.com).

Dr. Ellis has been very active in the Atlanta technology community since his arrival in 1979. He co-founded the MIT Enterprise Forum of Atlanta and, in 1998, received the Georgia Technology Forum award for “Outstanding Contribution to the Technology Industry.” He currently serves on the advisory board of the College of Sciences at Georgia Tech, as well as the advisory boards of the Shepherd Center and two Rehabilitation Engineering Research Centers. David’s memberships include the Technology Association of Georgia, the Technology Executive Roundtable, the British-American Business Group, and the Atlanta Venture Forum.

Arnoldo Hax is the Alfred P. Sloan Professor of Management at the Sloan School of Management of the Massachusetts Institute of Technology. He served as Deputy Dean of the Sloan School from 1987 through 1990. Prior to joining MIT in 1972, Dr. Hax was a faculty member at the Harvard Business School, and a senior consultant for Arthur D. Little, Inc.

He has published extensively in the fields of strategic management, management control, operations management, and operations research. He has authored and co-authored nine books, including The Delta Project: Discovering New Sources of Profitability in a Networked Economy with Dean Wilde, and about one hundred journal articles. An accomplished educator, he won the MIT-Sloan School’s Salgo Award for Excellence in Teaching.

Dr. Hax has wide consulting experience and has assisted many companies in developing formal strategic planning processes, including Synthes, Synthes Spine, Advanced Micro Devices, Eastman Chemical, Merck, EDS, Saturn, Coca-Cola, Digital Equipment Corporation, Motorola, General Motors, Citibank, Prime Computer, Searle, Analog Devices, Westinghouse Electric, Unilever, 3M, and Brown Boveri (Switzerland).

Dr. Hax is former Chairman of the Board of Sloan Management Review. In addition he is Strategic Management Editor for Interfaces and former editor of Operations Research, and Naval Research Logistics Quarterly. He is on the editorial board of the Journal of Manufacturing and Operations Research and the Journal of High Technology Management Research. He has been granted a Dean’s Award for Excellence at the Sloan School of Management and has been listed in Who’s Who in Science and Technology.

Steve Derezinski is currently Managing Director of Platform Technology Ventures, a venture creation group focused on forming spinouts based on patented university breakthroughs. He was CEO of Radiant Acoustics, a university-spinout creating high-performance nano-audio products based on patented technology. Steve provides InVivo Therapeutics with entrepreneurial advice on raising capital, engaging with universities and strategic partnerships. Steve Derezinski is graduate of the 2006 Fellow in the Sloan Fellows Program for Innovation and Global Leadership at the MIT Sloan School of Management. Prior to becoming a Sloan Fellow, Steve was Director of Georgia Tech’s VentureLab, a university-based commercialization program. During Steve’s tenure there, he started 8 companies which raised a combined total of $40M in series A venture backing. Steve is also a member of the National Association of Corporate Directors and has attended the Venture Capital Institute.

Steve has been a Director of the MIT Alumni/ae Association, District 7 Director as well as President of the MIT Club of Atlanta. Steve has his S.B. degree in Mechanical Engineering from MIT and an MBA from MIT Sloan School of Management.